NFL star Tom Brady and former X CEO Linda Yaccarino are launching a venture to provide a more sustainable use of GLP-1 weight loss drugs in a healthier way. eMed, which is currently raising $200 million and is valued at $2 billion, will use artificial intelligence and clinical oversight to assist employers in offering GLPs-1. However, Brady believes that personal accountability still matters and that discipline and hard work are something that we're born with. He emphasized the importance of good nutrition and discipline as a means of maximizing one's physical potential.